Live Breaking News & Updates on Justinev cohen

Stay informed with the latest breaking news from Justinev cohen on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Justinev cohen and stay connected to the pulse of your community

Communication Between Patients, Doctors Crucial After Melanoma Surgery

Patients with melanoma play a vital role in their own post-surgical care, as one expert from Dana-Farber Cancer Institute explained to CURE®.

Boston , Massachusetts , United-states , Dana-farber-cancer-institute , Justinev-cohen , Why-melanoma-may-need-treatment-after , Surgical-oncology , News , Cancer-horizons , Melanoma , Surgery

What's the Plan for Patients With Melanoma After Surgery?

“When we talk about recurrence of melanoma, we actually worry more about what we cannot see, what's on the inside,” Dr. Justine V. Cohen of the Dana-Farber Cancer Institute told CURE®.

Boston , Massachusetts , United-states , Dana-farber-cancer-institute , Justinev-cohen , Cancer-vaccine-plus-keytruda-reduces-risk , News , Video , Melanoma , Surgery , Skin

Immune therapy after surgery lowers relapse risk in patients with high-risk melanoma

E-Mail
IMAGE: Kenneth Grossmann, MD, PhD, of Huntsman Cancer Institute, led the SWOG S1404 clinical trial, which found that patients with high-risk melanoma who had pembrolizumab after their surgery had a longer...
view more
Credit: Huntsman Cancer Institute
PORTLAND, OR - Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021.
Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients three and one-half years after the last patient enrolled to the trial. They did find, however, that patients taking pembrolizumab had fewer serious side effects than those treated with either high-dose interferon or ipilimumab.

Colorado , United-states , Dana-farber-cancer-institute , Massachusetts , Megan-othus , Justinev-cohen , Johnm-kirkwood , Teresam-petrella , Antoni-ribas , Bartosz-chmielowski , Kennethf-grossmann , Kari-kendra